Rheumatoid Arthritis


Crystal ball gazing in RA: predicting who will respond to which targeted therapy, so we don’t have to do too much expensive trial-and-error.
This is by far the toughest of all RA clairvoyance acts, partly because we have so many treatment options, but mainly because we lack accessible and reliable biomarkers.
Case in point, we start with this biomarker: myeloid predominant synovitis predicts for better response to anti-TNF agents.

Researchers have identified DNA methylation as a potential biomarker of response to etanercept in an epigenome-wide association study of a longitudinal cohort of…
www.rheumatologynews.com|By NICOLA GARRETT

DNA methylation profiling: that is so accessible, seriously.

Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16.…
www.ncbi.nlm.nih.gov|By Daïen CI , et al.

High baseline NK cells level in peripheral blood predicts for response to anti-IL6.

Patients seropositive for rheumatoid factor or ACPA less likely to stop abatacept

RF and ACPA positivity predicts for good response to T-cell co-stimulation blockade as well as B-cell depletion.